Integrated Wealth Concepts LLC cut its holdings in Danaher Corporation (NYSE:DHR - Free Report) by 33.0% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 13,075 shares of the conglomerate's stock after selling 6,431 shares during the quarter. Integrated Wealth Concepts LLC's holdings in Danaher were worth $2,490,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

• The Often-Missed Corner of Healthcare That Wall Street Is Loving

A number of other hedge funds also recently bought and sold shares of the business. Main Street Group LTD bought a new stake in shares of Danaher in the 1st quarter worth approximately $25,000. N.E.W. Advisory Services LLC bought a new position in shares of Danaher during the second quarter valued at approximately $25,000. Hilton Head Capital Partners LLC purchased a new stake in Danaher in the fourth quarter worth $27,000. Clal Insurance Enterprises Holdings Ltd lifted its stake in Danaher by 71.6% in the fourth quarter. Clal Insurance Enterprises Holdings Ltd now owns 127 shares of the conglomerate's stock worth $29,000 after acquiring an additional 53 shares during the period. Finally, Evolution Wealth Management Inc. boosted its holdings in Danaher by 208.0% in the first quarter. Evolution Wealth Management Inc. now owns 154 shares of the conglomerate's stock valued at $29,000 after acquiring an additional 104 shares in the last quarter. Hedge funds and other institutional investors own 79.05% of the company's stock.

Danaher Stock Up 1.6%

NYSE:DHR opened at $203.44 on Tuesday. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.65 and a quick ratio of 1.25. The firm's 50-day moving average price is $202.85 and its 200-day moving average price is $191.91. The company has a market capitalization of $143.01 billion, a PE ratio of 36.13, a P/E/G ratio of 2.49 and a beta of 0.78. Danaher Corporation has a 1-year low of $160.93 and a 1-year high of $242.80.

• An AI Play Hiding in Plain Sight: A Look at Johnson Controls

Danaher (NYSE:DHR - Get Free Report) last issued its quarterly earnings results on Monday, July 20th. The conglomerate reported $1.94 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.85 by $0.09. The company had revenue of $6.26 billion during the quarter, compared to analysts' expectations of $6.12 billion. Danaher had a net margin of 15.95% and a return on equity of 11.04%. Danaher's revenue was up 5.5% on a year-over-year basis. During the same period last year, the company posted $0.77 EPS. On average, equities analysts predict that Danaher Corporation will post 8.53 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on DHR. Wells Fargo & Company reduced their price objective on shares of Danaher from $212.00 to $195.00 and set an "equal weight" rating on the stock in a research report on Wednesday, July 22nd. Stifel Nicolaus cut their target price on shares of Danaher from $260.00 to $220.00 and set a "buy" rating on the stock in a research note on Wednesday, July 22nd. DZ Bank initiated coverage on shares of Danaher in a research report on Wednesday, June 3rd. They set a "buy" rating and a $210.00 price target on the stock. Weiss Ratings raised shares of Danaher from a "sell (d+)" rating to a "hold (c-)" rating in a research note on Wednesday, July 15th. Finally, Citigroup initiated coverage on shares of Danaher in a report on Tuesday, May 26th. They issued a "buy" rating and a $230.00 price objective for the company. Two research analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and five have given a Hold rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $228.91.

• 3 Stocks Offering Strong Value and Stability

Read Our Latest Research Report on DHR

About Danaher

(Free Report)

Danaher Corporation NYSE: DHR is a global science and technology company that develops products, services and solutions for the life sciences, biotechnology and diagnostics markets. Its businesses support pharmaceutical and biotechnology research, biomanufacturing, clinical laboratories and healthcare providers.

The company's portfolio includes bioprocessing technologies, laboratory instruments, consumables, reagents and software. Key businesses include Cytiva, which provides biomanufacturing solutions; Beckman Coulter, which supplies laboratory diagnostics and automation systems; Leica Biosystems, which develops pathology products; and IDT, which provides genomic and nucleic acid products.

See Also

• Five stocks we like better than Danaher
• Analysts Are Punting Their Calls Into the Next Quarter After Adobe’s Mixed Earnings
• Institutional Money Is Pouring Into These 2 Altcoin ETFs
• The End of Big Tech Buybacks? Only One Hyperscaler Is Still Repurchasing Shares
• 3 Dividend Kings to Buy While They’re Still Beaten Down

Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Corporation (NYSE:DHR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Danaher Right Now?

Before you consider Danaher, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Danaher wasn't on the list.

While Danaher currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here